BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Global Biodefense - ECPv6.18.0//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Global Biodefense
X-ORIGINAL-URL:https://globalbiodefense.com
X-WR-CALDESC:Events for Global Biodefense
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20220313T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20221106T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20230312T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20231105T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221206T100000
DTEND;TZID=America/New_York:20221206T170000
DTSTAMP:20220921T172133Z
CREATED:20220921T171951Z
LAST-MODIFIED:20220921T172133Z
UID:56410-1670320800-1670346000@globalbiodefense.com
SUMMARY:FDA BAA Industry Day 2022
DESCRIPTION:The U.S. Food and Drug Administration FDA will host an Industry Day on 6 December 2022 to discuss a Broad Agency Announcement (BAA) for state of the art advancements in technology\, materials\, processes\, methods\, devices\, and techniques in pharmaceutical regulatory science. \nFDA funds extramural research through an agency-wide Broad Agency Announcement (BAA) for research and development to support regulatory science and innovation. Join the event to learn more about the FY 2023 BAA\, and how to apply. \nThe FDA BAA Industry Day 2022 will be held in virtual webcast format and is open to all responsible sources. Small businesses are strongly encouraged to participate. BAA Offerors may include single entities or teams from private sector organizations\, Federally Funded Research and Development Centers (FFRDCs)\, and academic institutions. \nThe FY 2023 FDA BAA has not yet been released at the time of this event listing (21 Sep 22). The FY 2022 FDA BAA is available here for reference.
URL:https://globalbiodefense.com/event/fda-baa-industry-day-2022/
CATEGORIES:Government Hosted,Industry Day
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2022/09/fda-baa-2022-industry-day-broad-agency-announcement.jpg
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221115
DTEND;VALUE=DATE:20221117
DTSTAMP:20220621T165636Z
CREATED:20220621T164935Z
LAST-MODIFIED:20220621T165636Z
UID:55684-1668470400-1668643199@globalbiodefense.com
SUMMARY:BARDA Industry Day 2022 - BID22
DESCRIPTION:The Biomedical Advanced Research and Development Authority (BARDA) 2022 Industry Day virtual event will be held 15-16 November 2022. \nBARDA\, a component of the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response (ASPR)\, invites you to participate in the annual conference to learn about U.S. Government medical countermeasure priorities\, interact with the BARDA and ASPR teams\, and network with public and private sector colleagues. \nThis year’s lineup will have an assortment of BARDA program briefings\, featured speakers\, special sessions\, and breakout sessions addressing efforts towards four strategic goals of enhancing preparedness\, response\, and partnerships against future threats. There will be a renewed focus on strengthening connections\, networking\, and collaboration within the virtual event environment. \n \nAt last year’s BARDA Industry Day event\, BARDA Director Dr. Gary Disbrow delivered a strategic overview of BARDA’s mission\, priorities and engagement during welcoming remarks. \nPlease visit the BARDA website for the latest updates.
URL:https://globalbiodefense.com/event/barda-industry-day-2022-bid22/
CATEGORIES:Government Hosted
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2022/06/barda-industry-day-2022-bid-november.jpg
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221109T090000
DTEND;TZID=America/New_York:20221109T170000
DTSTAMP:20220922T161453Z
CREATED:20220922T161453Z
LAST-MODIFIED:20220922T161453Z
UID:56463-1667984400-1668013200@globalbiodefense.com
SUMMARY:FDA Review: EUA for Oral Sabizabulin for High-Risk COVID-19 Patients
DESCRIPTION:The FDA’s Pulmonary-Allergy Drugs Advisory Committee Meeting will convene on 9 November 2022 to discuss the request for Emergency Use Authorization (EUA) for sabizabulin oral capsule\, a tubulin polymerization inhibitor\, submitted by Veru Inc.\, for the treatment of SARS-CoV-2 infection in moderate to severe COVID-19 infections at high risk of acute respiratory distress syndrome. \nSabizabulin is an oral\, novel microtubule disruptor that has dual antiviral and anti-inflammatory activities in preclinical models. \nA focus of the discussion will include the treatment effect size in the context of the high placebo mortality rate\, the limited size of the safety database\, and identifying the proposed population. \nInterested persons may present data\, information\, or views\, orally or in writing\, on issues pending before the committee. FDA is establishing a docket for public comment on this meeting. The docket number is FDA-2022-N-2107. \nPlease visit the FDA’s Meeting of the Pulmonary-Allergy Drugs Advisory Committee Meeting Announcement for more information.
URL:https://globalbiodefense.com/event/fda-review-eua-for-oral-sabizabulin-for-high-risk-covid-19-patients/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221109T083000
DTEND;TZID=America/New_York:20221109T161500
DTSTAMP:20220922T162918Z
CREATED:20220922T162826Z
LAST-MODIFIED:20220922T162918Z
UID:56465-1667982600-1668010500@globalbiodefense.com
SUMMARY:Considerations and Approaches for Obese Patient Populations in Drug Development Studies
DESCRIPTION:Obese patients are a large segment of the U.S. population and should be included in medical countermeasure and drug development studies. There are presently no clear dosing guidelines for obese pediatric patients. \nThe U.S. Food and Drug Administration (FDA) in collaboration with the University of Maryland Center of Excellence in Regulatory Science and Innovation (M-CERSI) will host a one-day virtual public workshop entitled “Bridging Efficacy and Safety to the Obese: Considerations and Scientific Approaches” on November 9\, 2022. The purpose of this workshop is to review the implications of obesity in adult and pediatric patients on safety\, efficacy\, drug dosing and disposition. \nBesides the major health and socioeconomic implications of obesity\, there are great challenges in ensuring the optimal use and development of drugs for the growing population of obese persons. Obese patients are a large segment of the U.S. population and should be included in drug development studies. There are presently no clear dosing guidelines for obese pediatric patients. Although smaller clinical studies have begun to examine drug pharmacokinetics in obese pediatric patients\, the relationship between pediatric obesity and drug response\, including efficacy and safety\, has not been thoroughly elucidated. Advancing this field requires identifying key knowledge gaps and barriers to the conduct of such studies and potential innovative solutions to improve data generation and analysis. \nThe workshop aims to: \n\nReview the implications of obesity in adult and pediatric patients on safety\, efficacy\, drug dosing and disposition.\nDiscuss whether adult and pediatric patients should be identified and studied as a special population in new drug development programs\nAddress when it may be appropriate to include obese patients in drug development studies to develop specific dosing guidelines for obese patients\n\nThe workshop which is jointly sponsored by the University of Maryland Center for Excellence in Regulatory Science and Innovation (M-CERSI) and the FDA\, will be open to the public. \nPlease visit the FDA’s Bridging Efficacy and Safety to the Obese: Considerations and Scientific Approaches event page for more information.
URL:https://globalbiodefense.com/event/considerations-and-approaches-for-obese-patient-populations-in-drug-development-studies/
CATEGORIES:Government Hosted,Workshop
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221102
DTEND;VALUE=DATE:20221104
DTSTAMP:20220922T163745Z
CREATED:20220922T163745Z
LAST-MODIFIED:20220922T163745Z
UID:56469-1667347200-1667519999@globalbiodefense.com
SUMMARY:Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting
DESCRIPTION:On November 2\, 2022\, the committee will discuss the Center for Drug Evaluation and Research (CDER) Quality Management Maturity (QMM) program. QMM is the state attained when drug manufacturers have consistent\, reliable\, and robust business processes to achieve quality objectives and promote continual improvement. CDER has proposed the development of a rating system that will help incentivize drug manufacturers to adopt more mature quality management practices at their facilities. The committee will consider the impact that a QMM program would have on the pharmaceutical industry\, drug shortages\, and supply chain resiliency. FDA will seek input to determine if experts from academia and industry support the development of a CDER QMM program to incentivize investments in mature quality management practices. \nOn November 3\, 2022\, as part of CDER’s continued effort to provide key updates on modernization of quality assessment\, the committee will discuss the next stages of Knowledge-Aided Assessment and Structured Application (KASA). The concept of KASA was envisioned in 2016 and discussed at the Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting on September 20\, 2018\, as an IT system that modernizes FDA’s assessment. Through the development\, testing\, and implementation of various KASA prototypes\, the KASA system has been refined over the course of multiple years. FDA will seek input on the vision and plan to expand KASA over the next 5 years to include drug substances\, all generic dosage forms\, new drug and biologics applications\, and post-approval changes. Moreover\, FDA will seek input regarding the need for advancing digitalization in KASA\, including data standardization and mobilization of data from cloud-based servers. \nInterested persons may present data\, information\, or views\, orally or in writing\, on issues pending before the committee. FDA is establishing a docket for public comment on this meeting. The docket number is FDA-2022-N-1777. \nPlease visit the FDA’s Pharmaceutical Science and Clinical Pharmacology Advisory Committee Meeting Announcement page for more information.
URL:https://globalbiodefense.com/event/pharmaceutical-science-and-clinical-pharmacology-advisory-committee-meeting/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221027
DTEND;VALUE=DATE:20221029
DTSTAMP:20220921T222128Z
CREATED:20220921T222128Z
LAST-MODIFIED:20220921T222128Z
UID:56444-1666828800-1667001599@globalbiodefense.com
SUMMARY:Best Practices: Modeling Approaches to Support Generic Product Development
DESCRIPTION:FDA and the Center for Research on Complex Generics (CRCG) will host a free public workshop on October 27-28\, 2022: Best Practices for Utilizing Modeling Approaches to Support Generic Product Development \nThe purpose of this two-day workshop is to discuss and illustrate how generic product developers can utilize modeling approaches in conjunction with in vitro data and other knowledge to support the development of complex generics that may otherwise rely upon challenging in vivo studies to demonstrate bioequivalence. \nThis workshop will engage experts from regulatory agencies\, the generic drug industry\, consultants\, academia\, and others in the field of modeling and simulation to discuss the opportunities and best practices for incorporating modeling and simulation approaches into generic drug development programs and regulatory submissions. The workshop will also identify commonalities in methodologies/workflows or in silico models supporting alternative BE approaches and clarify how a model master file may be leveraged to advance drug product development\, facilitate regulatory assessment\, and streamline drug product approval. \nFDA and the CRCG—which is a collaboration between the University of Maryland School of Pharmacy and the University of Michigan College of Pharmacy—are dedicated to advancing programs that stimulate scientific dialogue\, disseminate current insights about complex generics\, and generate new knowledge in support of FDA’s mission to promote and protect the public health by increasing access to safe and effective generic medicines. \nHighlighted topics include: \n\nUse of model integrated evidence to support demonstrations of BE in a regulatory context\nUse of the same or similar model or modeling strategy across multiple submissions related to complex drug products\nMechanistic modeling approaches supporting BE assessments for oral drug products\nApplications of quantitative comparative approaches to support the development of complex generic drug products\nCase examples supporting the recently introduced concept of “model master files”\n\nPlease visit the FDA’s Best Practices for Utilizing Modeling Approaches to Support Generic Product Development meeting page for information on registration.
URL:https://globalbiodefense.com/event/best-practices-modeling-approaches-to-support-generic-product-development/
CATEGORIES:Government Hosted,Webinar-Webcast
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2022/09/complex-genomics-modeling-approaches-generic-product-fda.jpg
LOCATION:https://umaryland.zoom.us/webinar/register/WN_QLkZn5TbTYqu4F986aKD6g
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221026
DTEND;VALUE=DATE:20221027
DTSTAMP:20220921T211348Z
CREATED:20220921T211237Z
LAST-MODIFIED:20220921T211348Z
UID:56442-1666742400-1666828799@globalbiodefense.com
SUMMARY:In-Depth Look at Final FDA Guidance: Bioavailability Studies Submitted in NDAs or INDs
DESCRIPTION:The FDA will host a meeting on 26 October 2022 to provide additional clarity to the final guidance with respect to Agency expectations for submissions containing Bioavailability information for drug products\, and will discuss: \n\nSelect case studies on various bioavailability (BA) related subtopics (e.g. pharmacodynamic (PD) endpoints\, endogenous compound Narrow Therapeutic Index (NTI)\, biowaivers).\nBioavailability Studies Submitted in NDAs and INDs – General Considerations\nBioavailability Determination: Special Topics\nRelative Bioavailability Evaluation: Potential for Using Pharmacodynamic and Non-Traditional Pharmacokinetic Endpoints\nRecommended In Vitro Studies\n\nThe intended audience for this event is: Regulatory Scientists assessing bioavailability studies as part of IND/NDA/BLA submissions; Research Coordinators overseeing in vivo studies in the context of IND/NDA/BLA submissions; Drug Development/New Drug industry scientists involved with bioavailability studies for support of a new/existing IND/NDA/BLA dossier; and foreign regulators. \nPlease visit the FDA’s In-Depth Look at BA Final Guidance Meeting website to register. \nFDA RESOURCES\nFinal Guidance for Industry: Bioavailability Studies Submitted in NDAs or INDs — General Considerations
URL:https://globalbiodefense.com/event/in-depth-look-at-final-fda-guidance-bioavailability-studies-submitted-in-ndas-or-inds/
CATEGORIES:Continuing Education,Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221024T110000
DTEND;TZID=America/New_York:20221024T172000
DTSTAMP:20220905T180114Z
CREATED:20220905T180114Z
LAST-MODIFIED:20220905T180114Z
UID:56285-1666609200-1666632000@globalbiodefense.com
SUMMARY:Board of Scientific Counselors\, National Center for Health Statistics
DESCRIPTION:The CDC has announced the Board of Scientific Counselors\, National Center for Health Statistics (BSC\, NCHS) will convene 24 October 2022 in a live broadcast public meeting. \nThe Board is charged with providing advice and making recommendations to the Secretary\, Department of Health and Human Services; the Director\, CDC; and the Director\, NCHS\, regarding the scientific and technical program goals and objectives\, strategies\, and priorities of NCHS. \nThe meeting agenda will include a Center update by the NCHS Director in addition to updates on NCHS data collection\, analysis\, and reporting activities\, including upcoming changes to the National Hospital Ambulatory Medical Care Survey (NHAMCS); status of a National Ambulatory Medical Care Survey (NAMCS) pilot and plans for obtaining clinician visit data; a new project to improve metadata and catalogs for the public to access restricted use data files; and new releases of linked data sets. The Board’s Workgroup to Consider and Assess Measures of Discrimination for Use in NCHS Surveys will brief the Board with findings from 6 months of information-gathering and assessment work. The Committee will reserve time for public comment at the end of the day. Meeting times and topics are subject to change as priorities dictate. \nMeeting Information: Please visit the BSC\, NCHS website for details. Further information and the meeting agenda will be available on the BSC website\, including instructions for accessing the live meeting broadcast.
URL:https://globalbiodefense.com/event/board-of-scientific-counselors-national-center-for-health-statistics/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221013T120000
DTEND;TZID=America/New_York:20221013T130000
DTSTAMP:20220921T205205Z
CREATED:20220921T205205Z
LAST-MODIFIED:20220921T205205Z
UID:56440-1665662400-1665666000@globalbiodefense.com
SUMMARY:Quality Considerations for MAM for Therapeutic Proteins
DESCRIPTION:The multi-attribute method (MAM) is a liquid chromatography-mass spectrometry (LC-MS) based peptide mapping approach used for the identification and quantitation of product quality attributes (PQAs) in therapeutic proteins. \nThe U.S. FDA Center for Drug Evaluation and Research (CDER)\, Emerging Technology Program (ETP) has assessed the use of MAM in quality control environments and laboratory resources have been developed to improve the FDA’s understanding of the approach. \nThis meeting will discuss: \n\nHow the LC-MS based multi-attribute method can be used for quality control of therapeutic proteins\nHow the multi-attribute method can detect multiple product quality attributes or critical quality attributes within a single LC-MS run\nKey considerations for implementation of the multi-attribute method\, including risk assessment\, method validation\, new peak detection\, and conventional method comparisons\n\nFor advance registration\, please visit the MAM for Therapeutic Proteins meeting page
URL:https://globalbiodefense.com/event/quality-considerations-for-mam-for-therapeutic-proteins/
CATEGORIES:Government Hosted
LOCATION:https://fda.zoomgov.com/webinar/register/WN_LKO4FXAlSfSuP89383sikg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221011
DTEND;VALUE=DATE:20221012
DTSTAMP:20220921T200930Z
CREATED:20220921T200613Z
LAST-MODIFIED:20220921T200930Z
UID:56431-1665446400-1665532799@globalbiodefense.com
SUMMARY:FDA NanoDay Symposium 2022
DESCRIPTION:The FDA NanoDay Symposium 2022 will be held on 11 October 2022. The event will address drug development of products that contain nanomaterials in their formulation and how the newly finalized guidance to industry for products that contain nanomaterials can be implemented in filings to the FDA. \nHighlighted topic areas include: \n\nPrimary Chemistry Manufacturing and Controls (CMC) and nonclinical hurdles for developing products that contain nanomaterials\nDevelopment and Characterization of Generic Drug Products Containing Nanomaterials\nConsiderations for the Quality\, Safety and Efficacy of Prophylactic Lipid Nanoparticle mRNA Vaccines\nCase studies on the development of the COVID mRNA lipid nanoparticle vaccine products\nFuture of Continuous Manufacturing of Drug Products Containing Nanomaterials\nEfforts to establish standards and standard methods for monitoring products that contain nanomaterials\nA contextualized discussion of the development of the COVID mRNA lipid nanoparticle vaccine products\nA nonclinical perspective of developmental challenges of products that contain nanomaterials\nSafety Evaluation of Food Contact Substances Containing Nanomaterials\n\nThe intended audience includes: Regulatory science and regulatory affairs professionals working on drug products\, including biologicals\, that contain nanomaterials and submit IND/NDA/BLA/ANDA applications for FDA review; researchers working on applications of nanotechnology for pharmaceutical products\, analytical methodology for control of pharmaceuticals that contain nanomaterials\, and nonclinical studies to support human clinical trials; and foreign regulators who review comparable pharmaceutical products that contain nanomaterials. \nPlease visit the FDA’s NanoDay Symposium 2022 website for more information. \nFDA RESOURCES\n\nGUIDANCE DOCUMENT: Drug Products\, Including Biological Products\, that Contain Nanomaterials – Guidance for Industry; APRIL 2022\nGUIDANCE DOCUMENT: Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology – Guidance for Industry; JUNE 2014\nGUIDANCE DOCUMENT: Liposome Drug Products: Chemistry\, Manufacturing\, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation; APRIL 2018\nGUIDANCE DOCUMENT: Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs\, Including Well-Characterized\, Therapeutic\, Biotechnology-derived Products – Guidance for Industry; NOVEMBER 1995
URL:https://globalbiodefense.com/event/fda-nanoday-symposium-2022/
CATEGORIES:Continuing Education,Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20221006T083000
DTEND;TZID=America/New_York:20221006T130000
DTSTAMP:20220921T202014Z
CREATED:20220921T201913Z
LAST-MODIFIED:20220921T202014Z
UID:56435-1665045000-1665061200@globalbiodefense.com
SUMMARY:VRBPAC Meeting - Vaccine Strain Selection 2023 Southern Hemisphere Flu Season
DESCRIPTION:The FDA Vaccines and Related Biological Products Advisory Committee will convene on 6 October 2022 in open session to discuss the Strain Selection for the Influenza Virus Vaccines for the 2023 Southern Hemisphere Influenza Season. \nMaterials for this meeting will be available at the Vaccines and Related Biological Products Advisory Committee meetings main page. Interested persons may present data\, information\, or views\, orally or in writing\, on issues pending before the committee. FDA is establishing a docket for public comment on this meeting. The Docket Number is FDA-2022-N-1745 \nPlease visit the FDA VRBPAC Meeting website for more information.
URL:https://globalbiodefense.com/event/vrbpac-meeting-vaccine-strain-selection-2023-southern-hemisphere-flu-season/
CATEGORIES:Government Hosted
LOCATION:https://youtu.be/qazitJMHZK4
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20221005
DTEND;VALUE=DATE:20221006
DTSTAMP:20220922T145702Z
CREATED:20220922T145702Z
LAST-MODIFIED:20220922T145702Z
UID:56457-1664928000-1665014399@globalbiodefense.com
SUMMARY:Study Data Standards Update for FDA CBER
DESCRIPTION:FDA’s Center for Biologics Evaluation and Research (CBER)  will host a free virtual format workshop on 5 October 2022 entitled Study Data Standards Update for CBER: Your Guide to a Successful Submission. \nCBER will discuss CBER’s support and requirement starting March 15\, 2023 for the Standard for the Exchange of Nonclinical Data (SEND) \, which was published in the Federal Register on July 14\, 2020\, and the addition of SEND for CBER to the FDA Data Standards Catalog. \nFDA will discuss the brief background of the new requirement and how SEND will aid CBER reviewers. The webinar will also address common issues in submission data. \nINTENDED AUDIENCE\n\nRegulatory science and regulatory affairs professionals working on clinical and non-clinical data submissions for BLAs/NDAs/ANDAs/INDs to CBER\nConsultants focused on clinical and non-clinical data submission\nHealthcare professionals specializing in clinical and non-clinical data\nForeign regulators\n\nFDA RESOURCES\n\nFederal Register Notice regarding SEND for CBER\nFDA Data Standards Catalog\nStudy Data Technical Conformance Guide\nFDA Study Data Standards Resources\nEmail: cber-edata@fda.hhs.gov\n\nPlease visit FDA’s Study Data Standards Update for CBER: Your Guide to a Successful Submission meeting webpage for more information.
URL:https://globalbiodefense.com/event/study-data-standards-update-for-fda-cber/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220929T110000
DTEND;TZID=America/New_York:20220929T150000
DTSTAMP:20220924T161732Z
CREATED:20220924T161603Z
LAST-MODIFIED:20220924T161732Z
UID:56507-1664449200-1664463600@globalbiodefense.com
SUMMARY:National Biodefense Science Board Public Meeting
DESCRIPTION:The next public meeting of the National Biodefense Science Board (NBSB) will take place on Thursday\, September 29. \nJoin NBSB members\, distinguished guests\, federal leaders\, and subject matter experts exploring topics such as how best to support rural and underserved communities during the COVID-19 pandemic\, use of virtual healthcare during disasters\, and health system operational data considerations during a health emergency. For additional details and meeting agenda topics\, please see the NBSB Public Meeting page. An agenda for the meeting is posted on the website. \nHighlighted agenda items include: \n\nReadiness and Resilience Working Group Readout\nCountermeasures and Operational Research Working Group Readout\nDisaster and Public Health Emergency Training Needs\, Challenges\, and Opportunities for the Health Workforce in the United States\nOpen Discussion – Additional Key Biodefense Lessons from COVID-19\n\nAdvanced registration is required. To register for the meeting and for additional information\, visit the NBSB Public Meeting page. \nRegister to Address the NBSB\nThe NBSB are inviting people with expertise or experience related to the collection\, analysis\, and operational use of health data to improve access to and resilience of virtual health care to address the Board and/or experience and expertise addressing rural and underserved communities during the COVID-19 pandemic. \nWe are particularly interested in hearing stakeholder input related to the following topics: \nOperational Health Data for Disaster Response\n\nWhat are your concerns about the confidentiality of your health data or how it might be used?\nWhat are your concerns with the current HHS data reporting requirements for health systems\, including the format\, timing\, and extent of data that must be submitted?\nShould data reporting requirements\, or modified requirements\, be continued after the COVID-19 reporting stops?\nWhat are the current training needs for healthcare staff to meet the requirements for collection and reporting of health data?\nWhat is the level of effort (i.e. staffing and person-time) required to satisfy all of the current health system reporting requirements?\nIf your health care or public health organization has agreements in place to share information among regional partners\, do you have processes in place to improve data sharing during a disaster? Has data sharing during disasters led to an improved disaster response?\nIf your health care or public health organization has agreements in place to share information among regional partners\, do you have any special measures in place to ensure that rural and underserved communities are represented?\n\nVirtual Healthcare for Disaster Response\n\nWhat could be done to improve the reliability and availability of internet access and the appropriate computers or software? If available\, is the use of telephone or radio an acceptable option for medical care during a disaster?\nWhat are your concerns about the continuity of care\, including the availability of your own medical history and proper recording of virtual care?\nAre there adequate resources in place to ensure that you receive the medications you need during a disaster?\nWould you be willing to have a “family visit” for healthcare\, where multiple people are treated on the same virtual visit?\n\nUpdate: NBSB currently has as many public speakers as can accommodated in the time available\, so please send written comments on related topics to NBSB@hhs.gov\, which will be shared with the board members ahead of the meeting. Additional meeting materials will be made available to the public on the NBSB Public Meeting page.
URL:https://globalbiodefense.com/event/national-biodefense-science-board-public-meeting-4/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220928
DTEND;VALUE=DATE:20220930
DTSTAMP:20240623T193106Z
CREATED:20220921T190315Z
LAST-MODIFIED:20240623T193106Z
UID:56428-1664323200-1664495999@globalbiodefense.com
SUMMARY:GBHI 2022 - 5th Annual Global Bioequivalence Harmonization Initiative Meeting
DESCRIPTION:The goal of the Global Bioequivalence Harmonization Initiative (GBHI) conference is to offer the most informative and up to date science and regulation of bioequivalence in global drug development.  \nThe FDA AAPS EUFEPS 5th Annual GBHI Meeting will be held 28-29 September 2022. GBHI workshop provides an open forum for pharmaceutical scientists from academia\, industry and regulatory agencies to discuss various bioequivalence topics at issue including: \n\nFed vs fasted studies for immediate release dosage forms\nRelevance of excipients\, disintegration/dissolution specificities\, drug substance properties and physiological GI conditions\nReplicate design for BE of Highly Variable Drugs\ntwo-stage design and Pharmacokinetic modelling as supportive tools for BE assessment\nScientifically-based approaches for a waiver of clinical endpoint trials\nStudy design and acceptance criteria\n\nThis conference is intended for leaders in Academia\, the Pharmaceutical and Biotechnology Industry (PhRMA\, BIO\, GPhA)\, contract research organizations\, API manufacturers\, and domestic and international regulatory agencies in positions to affect the science and regulation of drug discovery and development\, who wish to stay abreast of the national and international initiatives affecting the development of safe and effective pharmaceutical drug products. \nPlease visit the FDA’s Global Bioequivalence Harmonization Initiative (GBHI) conference website for more information.
URL:https://globalbiodefense.com/event/gbhi-2022-5th-annual-global-bioequivalence-harmonization-initiative-meeting/
CATEGORIES:Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220926T103000
DTEND;TZID=America/New_York:20220926T173000
DTSTAMP:20220907T151745Z
CREATED:20220907T151724Z
LAST-MODIFIED:20220907T151745Z
UID:56350-1664188200-1664213400@globalbiodefense.com
SUMMARY:IARPA PICARD Program Proposers' Day
DESCRIPTION:The IARPA Pursuing Intelligent Complex Aerosols for Rapid Detection (PICARD) program will host a Proposer’s Day on 26 September 2022 to introduce the PICARD program to potential proposers and to provide information on technical requirements and program objectives. The PICARD program intends to develop a fieldable sensing platform for the rapid identification of aerosol particles in plumes. This platform will address both point detection (in situ) and standoff detection capabilities that focus on the complexity of aerosols with non-uniform sizes\, structures\, and chemical composition as well as dispersion in challenging environments. \nThe goal of PICARD is to develop novel integrated hardware and software tools that will improve the current state of the art with respect to chemical specificity\, accuracy\, and sensitivity. \nThe PICARD Proposers’ Day is a hybrid event that will be broadcast via the Webex video conference platform for remote attendees. In person participation is encouraged to facilitate information exchange and team forming. For planning purposes\, the venue is located near the Ballston Metro Station in Arlington\, VA. A recorded video of the meeting will be made available to the public on the IARPA website after the event. \nProposers’ Day Registration Closes: Friday\, September 16\, 2022 at noon EDT. Please visit IARPA’s PICARD Proposers’ Day website for more information. \n 
URL:https://globalbiodefense.com/event/iarpa-picard-program-proposers-day/
LOCATION:Ballston Metro Station\, Arlington\, VA\, United States
CATEGORIES:Government Hosted
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2022/09/iarpa-picard-intelligent-complex-aerosol-rapid-detection.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220926
DTEND;VALUE=DATE:20220928
DTSTAMP:20220921T174333Z
CREATED:20220921T174333Z
LAST-MODIFIED:20220921T174333Z
UID:56420-1664150400-1664323199@globalbiodefense.com
SUMMARY:MAQC 2022 - Massive Analysis and Quality Control Society Conference
DESCRIPTION:The 5th Annual Meeting of the FDA/National Center for Toxicological Research (NCTR) – Massive Analysis and Quality Control Society (MAQC) 2022 Conference will be held September 26-27\, 2022\, at the U.S. FDA Headquarters\, White Oak Campus in Silver Spring MD. \nConference presentations\, abstracts\, and discussions will include themes around: Explainable/Reproducible AI/ML\, AI/ML in health-related datasets\, SARS-CoV-2 and public health\, Single-cell\, genomics\, image analysis\, reference samples\, reproducible science and more. \nHighlighted topics and presentations include: \n\nDARPA’s explainable AI (XAI) program: A retrospective\nDrug repurposing for COVID-19 using explainable machine learning and mechanistic models of signal transduction circuits related to SARS-CoV-2 infection with real world data validation\nAn automated bioinformatic software testing and benchmarking platform to standardize the development of accurate\, reproducible\, and scalable omics analysis tools\nLeaSH: a High-Throughput COVID-19 Test to Profile Viral and Host Transcriptomes by Next Generation\nSequencing\nSome non-obvious factors that enhance or diminish observed and theoretical Illumina library complexity\nAI or Animal – A reproducibility perspective\nReproducible AI for supporting regulatory applications – a case study\nImproving preclinical pathology analysis with PathologAI\nExplainable approach for species identification using LIME\nEvaluation of mutagenic susceptibility of different stages in germ cell development of Caenorhabditis elegans using next generation sequencing\nIntegrated Calling and Evaluation of Gene Fusion Detection by Targeted RNA Sequencing of Reference Samples with Long and Short Reads\nMutual genome and transcriptome enrichment and sequencing in single cells with ResolveOME amplification chemistry to illuminate complex biological mechanisms\n\nPlease visit the Massive Analysis and Quality Control Society (MAQC) 2022 Conference website for more information and to register.
URL:https://globalbiodefense.com/event/maqc-2022-massive-analysis-and-quality-control-society-conference/
LOCATION:FDA White Oak Campus\, 10903 New Hampshire Ave\, Silver Spring\, MD\, 20993\, United States
CATEGORIES:Government Hosted,Webinar-Webcast
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220922T143000
DTEND;TZID=America/New_York:20220922T153000
DTSTAMP:20220921T203623Z
CREATED:20220921T203623Z
LAST-MODIFIED:20220921T203623Z
UID:56437-1663857000-1663860600@globalbiodefense.com
SUMMARY:Navigating Avian Influenza: From Prevention to Recovery
DESCRIPTION:Hear insights and information from APHIS and other experts on steps to take and what to expect during a bird flu outbreak during a free webinar on 22 September 2022. \nLearn from USDA and other experts about how to keep your flocks safe from highly pathogenic avian influenza (HPAI). This session is for enthusiasts\, farmers\, educators\, and anyone interested in signs and symptoms of HPAI\, what to watch out for during fall migration\, and how to develop an effective biosecurity and response plan. Hear about one educational farm’s experience managing a potential HPAI outbreak and get tips on how to keep your poultry flocks safe. \nPlease register for the Navigating Avian Influenza webinar in advance.
URL:https://globalbiodefense.com/event/navigating-avian-influenza-from-prevention-to-recovery/
CATEGORIES:Government Hosted
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2022/09/navigating-avian-influenza-usda.jpg
LOCATION:https://us02web.zoom.us/webinar/register/WN_z8GAVnu2SkiAfdqfMXgK0g
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220922T083000
DTEND;TZID=America/New_York:20220922T170000
DTSTAMP:20220921T183353Z
CREATED:20220921T183322Z
LAST-MODIFIED:20220921T183353Z
UID:56423-1663835400-1663866000@globalbiodefense.com
SUMMARY:VRBPAC Meeting - Rebiotix Indication for Recurrent Clostridioides difficile Infection
DESCRIPTION:The Vaccines and Related Biological Products Advisory Committee (VRBPAC) will convene on 22 September 2022 to discuss the Biologics License Application # 125739 (BLA – 125739) from Rebiotix Inc. for a product\, Rebyota (Fecal Microbiota\, Live)\, with a requested indication to “reduce the recurrence of Clostridioides difficile infection (CDI) in adults following antibiotic treatment for recurrent Clostridioides difficile infection.” \nFDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting\, any background material will be made publicly available at the time of the advisory committee meeting\, and additional materials will be posted on FDA’s website after the meeting. \nInterested persons may present data\, information\, or views\, orally or in writing\, on issues pending before the committee. FDA is establishing a docket for public comment on this meeting. \nThe Docket Number is FDA-2022-N-1608.
URL:https://globalbiodefense.com/event/vrbpac-meeting-rebiotix-indication-for-recurrent-clostridioides-difficile-infection/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:https://www.youtube.com/watch?v=vrahKrbyJaU
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220921T120000
DTEND;TZID=America/New_York:20220921T130000
DTSTAMP:20220921T172921Z
CREATED:20220921T172727Z
LAST-MODIFIED:20220921T172921Z
UID:56416-1663761600-1663765200@globalbiodefense.com
SUMMARY:Virtual Town Hall Series - Monkeypox Test Development and Validation
DESCRIPTION:The U.S. Food and Drug Administration (FDA) will host a virtual town hall for monkeypox test developers on 21 September 2022. The purpose of these town halls is to help answer technical questions about the development and validation of tests for monkeypox. \nThe FDA plays a critical role in protecting the United States from threats such as emerging infectious diseases\, including monkeypox . The FDA is committed to providing timely guidance to support response efforts to this public health emergency. \nThe guidance\, Policy for Monkeypox Tests to Address the Public Health Emergency\, includes policies specific to this public health emergency. \nThe FDA hosted a webinar on September 14\, 2022\, to discuss highlights of and answer questions about the final guidance. The presentation\, printable slides\, and transcript from that webinar are available at CDRH Learn under “Specialty Technical Topics”\, sub-section “Public Health Emergencies.”
URL:https://globalbiodefense.com/event/virtual-town-hall-series-monkeypox-test-development-and-validation/
CATEGORIES:Conference,Government Hosted
LOCATION:https://fda.zoomgov.com/j/1612083563?pwd=NklWOE1jUlU2dUVlNWtvQTNkdTM5UT09#success
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220921
DTEND;VALUE=DATE:20220923
DTSTAMP:20220420T212311Z
CREATED:20220420T212042Z
LAST-MODIFIED:20220420T212311Z
UID:54799-1663718400-1663891199@globalbiodefense.com
SUMMARY:Scientific Advisory Committee on Alternative Toxicological Methods (SACATM) Meeting
DESCRIPTION:The Scientific Advisory Committee on Alternative Toxicological Methods will meet 21-22 September 2022. \nThis is a Save-the-Date posting. Further details will be made available at the National Toxicology Program website closer to the meeting date.
URL:https://globalbiodefense.com/event/scientific-advisory-committee-on-alternative-toxicological-methods-sacatm-meeting/
CATEGORIES:Conference,Government Hosted
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20220912
DTEND;VALUE=DATE:20220914
DTSTAMP:20220830T001753Z
CREATED:20220830T001521Z
LAST-MODIFIED:20220830T001753Z
UID:56267-1662940800-1663113599@globalbiodefense.com
SUMMARY:Presidential Advisory Council on Combating Antibiotic Resistant Bacteria
DESCRIPTION:The 21st Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB) public meeting is tentatively being planned as an in-person event on September 12 and September 13\, 2022. The meeting will focus on pandemic preparedness and AMR policy. \nHighlighted topics include: \n\nUnderstanding the Human Diagnostic Communication Network (Labs\, Public Health Departments\, and Providers)\nInfection Prevention and Control for Resistant Pathogens during a Medical Surge\nLeveraging the Existing Pipeline of Available Vaccines and Therapeutics while Developing New AMR MCMs (Human)\nDeveloping New Human Diagnostics in an Emergency Situation: What’s Expected\, Needed\, and How We Get What We Need\nA Pandemic Response from a Global Perspective\nThe Agricultural Workforce: Human Health Risk and the Role of Workers as Vectors of Transmission\nThe Role of Associations in Pandemic Response and Dissemination of Information\nImpact of a Public Health Emergency on Human Antibiotic Stewardship Practices\nDiagnosing Fungal Infections and Resistance with our Current Diagnostic Capacity\nThe Role of Diagnostics in Herds: Availability\, Challenges\, and How They’re Used\nThe Federal Strategy for Animal Surveillance\, Information Sharing\, and Disseminating Guidance\nRecognizing the Pandemic: Identifying the “AMR Pandemic” within the Pandemic and Disseminating Information and Guidance\nLeveraging Current Human Antibiotic-Use-Monitoring for AMR Pandemic Surveillance\nRecognizing the Pandemic: Producer Surveillance Methods and Identifying Secondary AMR infections in Animal Production\nDevelopment of New Animal Vaccines and Understanding Federal Regulations\nUnderstanding the Animal Diagnostic Communication Network (Labs\, Producers\, and Veterinarians)\nSources of Environmental Contamination and the Potential for Surveillance\n\nThis meeting is open to the public. Members of the public can choose to attend in-person (attendance will be limited) or view the meeting via webcast. Please visit the HHS 21st Presidential Advisory Council on Combating Antibiotic Resistant Bacteria (PACCARB) website to register.
URL:https://globalbiodefense.com/event/paccarb-public-meeting-presidential-advisory-council-on-combating-antibiotic-resistant-bacteria/
LOCATION:Tysons Corner Marriott\, 8028 Leesburg Pike\, Tysons Corner\, VA\, 22182-2719\, United States
CATEGORIES:Conference,Government Hosted
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220830T083000
DTEND;TZID=America/New_York:20220830T170000
DTSTAMP:20240623T192753Z
CREATED:20220829T230154Z
LAST-MODIFIED:20240623T192753Z
UID:56260-1661848200-1661878800@globalbiodefense.com
SUMMARY:Drug Development Considerations for the Prevention of Healthcare Associated Infections
DESCRIPTION:The Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) are co-sponsoring this public virtual workshop on August 30\, 2022. All meeting materials—including agenda\, panelist affiliations/disclosures\, speaker slides\, workshop recording\, and transcript—will be posted here shortly before and/or after the completion of the workshop. \n\nThe current state of development of pathogen-directed products used to prevent healthcare-associated infections (HAIs).\nEvidence supporting decolonization and pathogen reduction (in colonized patients) as a strategy to prevent infection and transmission of antimicrobial-resistant healthcare-associated pathogens.\nAntimicrobial resistance threats as potential targets for decolonization and pathogen reduction.\nChallenges and potential approaches to drug development and registration of products for the prevention of healthcare-associated infections.\n\nThis meeting will be held in virtual format only. Registration is required for online attendance and will be available until 12 p.m. EDT on August 29\, 2022.
URL:https://globalbiodefense.com/event/drug-development-considerations-for-the-prevention-of-healthcare-associated-infections/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220629T120000
DTEND;TZID=America/New_York:20220629T170000
DTSTAMP:20220622T153805Z
CREATED:20220622T153805Z
LAST-MODIFIED:20220622T153805Z
UID:55703-1656504000-1656522000@globalbiodefense.com
SUMMARY:USG Policies for the Oversight of Life Sciences Dual Use Research of Concern
DESCRIPTION:The purpose of this meeting is to gather feedback from stakeholders about their experiences implementing these policies\, the effect of these policies in terms of achieving their stated goals\, the overarching definition of DURC\, and possible alternative approaches for the oversight and responsible conduct of DURC. \nThis feedback will also be used to inform the discussions of the National Science Advisory Board for Biosecurity (NSABB) in fulfillment their current charge to evaluate and analyze the DURC policies. \nRegistration is not required to view the webcast. \nREAD MORE: Dual Use Research of Concern: NIH to Host Stakeholder Engagement Meeting on Oversight Policies
URL:https://globalbiodefense.com/event/usg-policies-for-the-oversight-of-life-sciences-dual-use-research-of-concern/
CATEGORIES:Conference,Government Hosted
LOCATION:https://osp.od.nih.gov/event/virtual-stakeholder-engagement-meeting-on-usg-policies/
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220628T083000
DTEND;TZID=America/New_York:20220628T170000
DTSTAMP:20220527T213139Z
CREATED:20220527T213139Z
LAST-MODIFIED:20220527T213139Z
UID:55118-1656405000-1656435600@globalbiodefense.com
SUMMARY:VRBPAC Meeting on COVID-19 Vaccine Strain Composition Decisions
DESCRIPTION:The VRBPAC will meet in open session on 28 June 2022 to discuss whether and how the SARS-CoV-2 strain composition of COVID-19 vaccines should be modified. \nFDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its website prior to the meeting\, any background material will be made publicly available at the time of the advisory committee meeting\, and additional materials will be posted on FDA’s website after the meeting. \nMaterials for this meeting will be available at the Vaccines and Related Biological Products Advisory Committee meetings main page. \nInterested persons may present data\, information\, or views\, orally or in writing\, on issues pending before the committee. FDA is establishing a docket for public comment on this meeting. \nThe Docket Number is FDA-2022-N-0905
URL:https://globalbiodefense.com/event/vrbpac-meeting-on-covid-19-vaccine-strain-composition-decisions/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:https://www.youtube.com/watch?v=BFdzNUus_CE
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220615T083000
DTEND;TZID=America/New_York:20220615T170000
DTSTAMP:20220527T210409Z
CREATED:20220527T210409Z
LAST-MODIFIED:20220527T210409Z
UID:55115-1655281800-1655312400@globalbiodefense.com
SUMMARY:VRBPAC Meeting to Review Pediatric (Infant - 5 Years) mRNA Vaccines
DESCRIPTION:The VRBPAC will meet in open session to discuss amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 5 years of age\, and also to discuss amending the EUA of the Pfizer-BioNTech COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 4 years of age. \nFDA intends to make background material available to the public no later than 2 business days before the meeting.  If FDA is unable to post the background material on its website prior to the meeting\, any background material will be made publicly available at the time of the advisory committee meeting\, and additional materials will be posted on FDA’s website after the meeting. \nMaterials for this meeting will be available at the Vaccines and Related Biological Products Advisory Committee meetings main page. \nInterested persons may present data\, information\, or views\, orally or in writing\, on issues pending before the committee. FDA is establishing a docket for public comment on this meeting. The Docket Number is FDA-2022-N-0904.
URL:https://globalbiodefense.com/event/vrbpac-meeting-to-review-pediatric-infant-5-years-mrna-vaccines/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:https://www.youtube.com/watch?v=Ixm4UmldTGQ
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220614T083000
DTEND;TZID=America/New_York:20220614T170000
DTSTAMP:20220527T205853Z
CREATED:20220527T205356Z
LAST-MODIFIED:20220527T205853Z
UID:55113-1655195400-1655226000@globalbiodefense.com
SUMMARY:VRBPAC Meeting to Review Moderna Pediatric (Ages 6-17) mRNA Vaccine EAU
DESCRIPTION:The VRBPAC committee will meet in open session on June 14\, 2022 to discuss amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to children and adolescents 6 years through 17 years of age. \nFDA intends to make background material available to the public no later than 2 business days before the meeting.  If FDA is unable to post the background material on its website prior to the meeting\, any background material will be made publicly available at the time of the advisory committee meeting\, and additional materials will be posted on FDA’s website after the meeting. \nMaterials for this meeting will be available at the Vaccines and Related Biological Products Advisory Committee meetings main page. \nInterested persons may present data\, information\, or views\, orally or in writing\, on issues pending before the committee. FDA is establishing a docket for public comment on this meeting. The Docket Number is FDA-2022-N-0904 \nOn June 15\, 2022\, under Topic II\, the committee will meet in open session to discuss amending the EUA of the Moderna COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 5 years of age\, and also to discuss amending the EUA of the Pfizer-BioNTech COVID-19 mRNA vaccine to include the administration of the primary series to infants and children 6 months through 4 years of age. \n  \n  \n 
URL:https://globalbiodefense.com/event/vrbpac-meeting-to-review-moderna-pediatric-ages-6-17-mrna-vaccine-eau/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:https://www.youtube.com/watch?v=GbNpaZeDPiA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220330T130000
DTEND;TZID=America/New_York:20220330T153000
DTSTAMP:20220323T181737Z
CREATED:20220323T163049Z
LAST-MODIFIED:20220323T181737Z
UID:54546-1648645200-1648654200@globalbiodefense.com
SUMMARY:Inaugural Joint Meeting of NACSD and NACIDD
DESCRIPTION:Please join Assistant Secretary for Preparedness and Response Dawn O’Connell along with Assistant Secretary for Aging and Acting Administrator for Community Living Alison Barkoff\, Wednesday\, March 30 from 1:00 p.m. to 3:30 p.m. ET for the inaugural meeting of the National Advisory Committee on Seniors and Disasters (NACSD) and National Advisory Committee on Individuals with Disabilities and Disasters (NACIDD). \nAdvanced registration for this meeting is required and can be accessed\, along with additional meeting information\, through the online event page. \nDuring this joint meeting\, committee members will be sworn into service and begin a national discussion with federal subject matter experts on the challenges\, opportunities\, and priorities in meeting the unique health needs of older adult populations and people with disabilities during and after disasters and public health emergencies. \nThe agenda includes time to hear from the public. The floor will be open to hear as many relevant comments as possible. To learn how to request a speaking time\, please visit our event page. Meeting materials also will be made publicly available through that page. You can send questions about the NACSD to NACSD@hhs.gov and questions about the NACIDD to NACIDD@hhs.gov. \nBackground \nThe National Advisory Committee on Seniors and Disasters (NACSD) and the National Advisory Committee on Individuals With Disabilities and Disasters (NACIDD)\, or Committees\, were established by sections 2811B and 2811C\, respectively\, of the Public Health Service (PHS) Act\, as amended by the Pandemic and All Hazards Preparedness and Advancing Innovation Act (PAHPAIA) of 2019. The Committees are governed by the provisions of the Federal Advisory Committee Act (FACA) and the General Services Administration FACA Final Rule. The Committees evaluate issues and programs and provide findings\, advice\, and recommendations to the Secretary of HHS to support and enhance all-hazards public health and medical preparedness\, response\, and recovery. The NACSD provides focus on the unique needs of older adults\, while the NACIDD focuses on helping HHS meet the needs of people with disabilities (PWD). The Secretary of HHS has formally delegated authority to operate the NACSD and the NACIDD to ASPR. \nFor Further Information:\nDr. Maxine Kellman\, NACSD Designated Federal Official\, 202-260-0447\, NACSD@hhs.gov; Tabinda Burney\, NACIDD Designated Federal Official\, 202-699-1779\, NACIDD@hhs.gov. Office of the Assistant Secretary for Preparedness and Response (ASPR)\, Department of Health and Human Services (HHS)\, Washington\, DC. \nLearn more and register at the ASPR website \n 
URL:https://globalbiodefense.com/event/national-advisory-committee-on-seniors-and-disasters-nacsd-and-national-advisory-committee-on-individuals-with-disabilities-and-disasters-nacidd/
CATEGORIES:Conference,Government Hosted
ATTACH;FMTTYPE=image/jpeg:https://globalbiodefense.com/wp-content/uploads/2022/03/nacidd-individuals-disabilities-disasters-seniors-disasters-aspr.jpg
LOCATION:https://hhsasproea.zoomgov.com/webinar/register/WN_qCfSOHCWT4qTywRzWw_3fA
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20220307T133000
DTEND;TZID=America/New_York:20220307T150000
DTSTAMP:20220305T134424Z
CREATED:20220303T133528Z
LAST-MODIFIED:20220305T134424Z
UID:54171-1646659800-1646665200@globalbiodefense.com
SUMMARY:National Biodefense Science Board Public Meeting
DESCRIPTION:The next public meeting of the National Biodefense Science Board (NBSB) will take place Monday\, 7 March 2022 from 1:30pm – 3:00pm ET via Zoom. \nJoin federal leaders\, National Biodefense Science Board members\, distinguished guests\, and other experts to discuss topics related to the public health supply chain and climate change.  NBSB will hear from the HHS Office of Climate Change and Health Equity and Joint Program Executive Office for Chemical\, Biological\, Radiological\, and Nuclear Defense (JPEO-CBRND) during the meeting. \nSubject matter experts from industry; academia; health systems; health consumer organizations; state\, local\, tribal\, and territorial public health; and emergency management agencies will also have an opportunity to provide comments to the NBSB on national priorities for biodefense and health security. Individual remarks will be limited to seven minutes each and the display of images and/or slides for public speakers will not be available. \nRequests to provide remarks to the NBSB during the public meeting must be sent to NBSB@hhs.gov by March 4\, 2022. In that request\, please provide the speaker’s name\, title\, and position with a brief summary of planned comments. The number of speakers and topics will be based on relevance to the mission of the NBSB and amount of time available on the agenda.  Those selected for public comments will receive confirmation by email prior to the meeting date with additional instructions. \nRegistration for this event is required and can be accessed along with additional meeting information through the online event page.  We encourage you to share this engagement information broadly across your network in advance of the meeting. \nMeeting materials will be made available to the public on the National Biodefense Science Board webpage. For any additional information or questions specific to this event\, please contact NBSB@hhs.gov directly.
URL:https://globalbiodefense.com/event/national-biodefense-science-board-public-meeting-3/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:https://hhsasproea.zoomgov.com/webinar/register/WN_DdvW3yVpTuGWSIey8ZsfBg
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20211216
DTEND;VALUE=DATE:20211217
DTSTAMP:20211106T220805Z
CREATED:20211106T220727Z
LAST-MODIFIED:20211106T220805Z
UID:50876-1639612800-1639699199@globalbiodefense.com
SUMMARY:National Biodefense Science Board Meeting
DESCRIPTION:The National Biodefense Science Board (NBSB) will meet in public (virtually) on December 16\, 2021\, to provide advice and recommendations to ASPR regarding the development of the 2023-2026 National Health Security Strategy and to discuss other matters of current important for public health emergency preparedness\, response\, and recovery. \n\n\n\nA more detailed agenda will be available on the NBSB meeting website https://www.phe.gov/​nbsb. \n\n\n\nProcedures for Public Participation\n\n\n\nMembers of the public may attend the meeting via a toll-free phone number or Zoom teleconference\, which requires pre-registration. The meeting link to pre-register will be posted on the meeting website https://www.phe.gov/​nbsb. Members of the public may provide written comments or submit questions for consideration by the NBSB at any time via email to NBSB@hhs.gov. \nSource: Federal Register Notice
URL:https://globalbiodefense.com/event/national-biodefense-science-board-meeting/
CATEGORIES:Government Hosted,Webinar-Webcast
LOCATION:
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20211208T090000
DTEND;TZID=America/New_York:20211208T103000
DTSTAMP:20240623T192553Z
CREATED:20211005T192345Z
LAST-MODIFIED:20240623T192553Z
UID:50043-1638954000-1638959400@globalbiodefense.com
SUMMARY:Current Concepts in Quantitative Risk Assessment for Skin Sensitization
DESCRIPTION:The NTP Interagency Center for the Evaluation of Alternative Toxicological Methods (NICEATM) is partnering with the Swiss Centre for Applied Human Toxicology and the Swiss State Secretariat for Economic Affairs to present a webinar series on “Current Concepts in Quantitative Risk Assessment for Skin Sensitization.” \nThe next webinar in the series on December 8 will consider the topics of methods for skin sensitization hazard and potency determination using currently available non-animal test methods\, as well as exposure assessment and quantification. \nThe webinar series is free and open to the public. Those who registered to view the first webinar are automatically registered for the second webinar. \nInformation and a link to register are available at https://ntp.niehs.nih.gov/go/ssqra-web. A video from the first webinar in the series\, which presented an introduction to skin sensitization and contact dermatitis\, will be posted on this page when available. \nRegister for the December 8 webinar: “Methods for hazard and exposure assessment”
URL:https://globalbiodefense.com/event/current-concepts-in-quantitative-risk-assessment-for-skin-sensitization/
CATEGORIES:Conference,Government Hosted,Webinar-Webcast
LOCATION:
END:VEVENT
END:VCALENDAR